Bluefin Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History

Bluefin Capital Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,790	Closed	-$946K	–	432
2020 Q2	$40K	Sell	8,790 -1,390	-14%	-$152K	﹤0.01%	310
2020 Q1	$7K	Buy	10,180 +20	+0.2%	+$2.14K	﹤0.01%	389
2019 Q4	$16K	Hold	10,160	–	–	﹤0.01%	511
2019 Q3	$17K	Hold	10,160	–	–	﹤0.01%	448
2019 Q2	$24K	Buy	+10,160	New	+$1.06M	﹤0.01%	284
2019 Q1	–	Sell	-10,160	Closed	-$39K	–	471
2018 Q4	$39K	Hold	10,160	–	–	﹤0.01%	330
2018 Q3	$32K	Hold	10,160	–	–	﹤0.01%	419
2018 Q2	$36K	Hold	10,160	–	–	﹤0.01%	359
2018 Q1	$33K	Buy	10,160 +2,160	+27%	+$211K	﹤0.01%	354
2017 Q4	$776K	Buy	+8,000	New	+$774K	0.05%	192

Other funds holding NRXP

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Bluefin Capital Management's NRXP Position: Q3 2020 in Review

Bluefin Capital Management sold out of NRX Pharmaceuticals (NRXP) in Q3 2020, closing a stake of 8,790 shares — an estimated $946K sold.

Bluefin Capital Management first reported a position in NRXP in Q4 2017 and held it in 10 quarters. The position peaked at $776K in Q4 2017. 5 funds tracked by Wall St. Rank hold NRXP as of Q3 2020.

Bluefin Capital Management reported no remaining NRX Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bluefin Capital Management sold 8,790 NRX Pharmaceuticals shares in Q3 2020, an estimated $946K.
Bluefin Capital Management first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Bluefin Capital Management's NRX Pharmaceuticals position peaked at $776K in Q4 2017.
5 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2020.

Based on Bluefin Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.